• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»vision correction

Johnson & Johnson’s TECNIS PureSee approval highlights the evolving battle between EDOF and multifocal cataract lenses

By Pallavi Madhiraju on March 13, 2026   Medical Devices & Diagnostics  

Johnson & Johnson’s TECNIS PureSee approval highlights the evolving battle between EDOF and multifocal cataract lenses

Johnson & Johnson wins FDA approval for TECNIS PureSee IOL. Discover what this extended depth of focus cataract lens means for surgeons and patients.

Can Cataltheia’s Deseyne lens replace multifocal optics in age-related vision correction?

By Pallavi Madhiraju on January 1, 2026   Medical Devices & Diagnostics  

Can Cataltheia’s Deseyne lens replace multifocal optics in age-related vision correction?

FDA clears Deseyne, the first EDOF contact lens for presbyopia. Find out how it could reshape non-surgical vision correction in the U.S. market.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes